Gujarat Themis Biosyn Q2 FY27 Investor Presentation: Standalone Revenue Up 12%
Gujarat Themis Biosyn reported a 12% YoY increase in standalone revenue for Q2 FY27 to ₹47.5 crore, and 17% for H1 FY27. H1 FY27 revenue was ₹91 crore, with EBITDA up 11% to ₹39 crore. The company commissioned a new fermentation facility and acquired MicroBiopharm Japan for JPY 21.5 billion (~₹1,300 crore). Additionally, an agreement to acquire select products from Sanofi for ~EUR 158 million was announced.
The announcement includes significant strategic developments such as the acquisition of MicroBiopharm Japan and the agreement with Sanofi, which are expected to materially expand the company's product portfolio, market reach, and capabilities. The commissioning of a new fermentation facility also points to future growth potential.
The company reported positive revenue growth driven by strong volumes and a favorable product mix. The commissioning of a new facility and strategic acquisitions are seen as drivers for future growth, despite some near-term margin impacts. The Sanofi deal further enhances market access and product portfolio.
Gujarat Themis Biosyn Limited has released its Investor Presentation for the quarter and half-year ended September 30, 2026. The company reported a healthy business momentum with standalone revenue growing 12% year-on-year in Q2 FY27 and 17% in H1 FY27, driven by strong volume and a favorable shift towards APIs.
The company commissioned its new fermentation facility, which is expected to strengthen manufacturing capabilities. While this had a near-term impact on operating margins, benefits are anticipated from Q4 FY27 onwards as capacity utilization increases.
Strategically, the acquisition of MicroBiopharm Japan (MBJ) is highlighted as an opportunity to expand capabilities in anti-infectives and fermentation, and enhance global presence. The integration of MBJ and leveraging combined capabilities are key focus areas.
Financially, H1 FY27 revenue stood at ₹91 crore, with EBITDA increasing 11% year-on-year to ₹39 crore. The management noted that near-term profitability was affected by the new facility commissioning and acquisition-related financing costs. They expect operating performance to strengthen progressively.
Looking ahead, the company's priorities include precision fermentation, bioconversion, gene therapy, anti-infectives, and biopeptides, supported by R&D, capacity utilization, and operational efficiency.
The company also announced an agreement with Sanofi to acquire a select product portfolio for approximately EUR 158 million, funded by a mix of debt and equity. This acquisition includes 13 established global brands in tuberculosis and anti-infectives, aiming for immediate global market access and long-term margin expansion.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.